Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more
Ilsung Pharm (003120) - Total Assets
Latest total assets as of September 2025: ₩390.07 Billion KRW
Based on the latest financial reports, Ilsung Pharm (003120) holds total assets worth ₩390.07 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ilsung Pharm - Total Assets Trend (2013–2024)
This chart illustrates how Ilsung Pharm’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ilsung Pharm - Asset Composition Analysis
Current Asset Composition (December 2024)
Ilsung Pharm's total assets of ₩390.07 Billion consist of 68.2% current assets and 31.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 27.8% |
| Accounts Receivable | ₩15.09 Billion | 3.8% |
| Inventory | ₩28.24 Billion | 7.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.74 Billion | 0.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Ilsung Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ilsung Pharm's current assets represent 68.2% of total assets in 2024, an increase from 37.1% in 2013.
- Cash Position: Cash and equivalents constituted 27.8% of total assets in 2024, up from 1.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 7.1% of total assets.
Ilsung Pharm Competitors by Total Assets
Key competitors of Ilsung Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Ilsung Pharm - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ilsung Pharm generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Ilsung Pharm generates $ 3.30 in net profit.
Ilsung Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.07 | 22.43 | 15.65 |
| Quick Ratio | 20.80 | 19.86 | 14.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩255.06 Billion | ₩ 259.57 Billion | ₩ 246.42 Billion |
Ilsung Pharm - Advanced Valuation Insights
This section examines the relationship between Ilsung Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.44 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.3% |
| Total Assets | ₩396.88 Billion |
| Market Capitalization | $38.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ilsung Pharm's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Ilsung Pharm's assets decreased by 5.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ilsung Pharm (2013–2024)
The table below shows the annual total assets of Ilsung Pharm from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩396.88 Billion | -5.32% |
| 2023-12-31 | ₩419.19 Billion | -15.22% |
| 2022-12-31 | ₩494.42 Billion | +33.13% |
| 2021-12-31 | ₩371.38 Billion | +0.04% |
| 2020-12-31 | ₩371.22 Billion | +0.46% |
| 2019-12-31 | ₩369.52 Billion | +6.41% |
| 2018-12-31 | ₩347.26 Billion | -0.06% |
| 2017-12-31 | ₩347.46 Billion | +2.65% |
| 2016-12-31 | ₩338.50 Billion | -7.77% |
| 2015-12-31 | ₩367.03 Billion | -3.00% |
| 2014-12-31 | ₩378.37 Billion | +1.53% |
| 2013-12-31 | ₩372.66 Billion | -- |